Jenscare Scientific Co. Ltd. Class H (HK:9877) has released an update.
Jenscare Scientific Co. Ltd. has released encouraging six-month follow-up results from their TRAVEL II clinical trial, showing 97% device success and marked improvements in patients with severe tricuspid regurgitation. This includes significant enhancements in cardiac function and quality of life, with a promising safety profile for the LuX-Valve Plus, a transvascular tricuspid valve replacement system.
For further insights into HK:9877 stock, check out TipRanks’ Stock Analysis page.
